NDA 208036 · Bracco
E-Z-Cat Dry
Barium Sulfate · Oral · Radiographic Contrast Agent
Last checked: Nov 20, 2026Latest source record: Apr 30, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Jan 11, 2016
Approved uses
4
Original approval plus efficacy supplements
Registered trials
25
4 Phase 3, 5 recruiting
FAERS reports
351
260 serious, 31 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 15, 2026.
VARIBAR THIN LIQUID is indicated for modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients. VARIBAR THIN LIQUID is a radiopaque contrast agent indicated for use in modified barium swallow examinations to evaluate the oral and pharyngeal function and morphology in adult and pediatric patients ( 1 )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 30, 2019 Supplement 10 · Efficacy LabelLetter
- Apr 7, 2017 Supplement 5 · Efficacy LabelLetter
- Jan 3, 2017 Supplement 2 · Efficacy LabelLetter
- Jan 11, 2016 Original approval · Type 7 - Drug Already Marketed without Approved NDA LabelReviewPediatric Medical Review
4 products under this application
- E-Z-CAT DRY · BARIUM SULFATE 40% · FOR SUSPENSION, ORAL · Discontinued
- E-Z-HD · BARIUM SULFATE 98% · FOR SUSPENSION, ORAL · Prescription
- VARIBAR THIN LIQUID · BARIUM SULFATE 81% · FOR SUSPENSION, ORAL · Prescription
- E-Z-PAQUE · BARIUM SULFATE 96% · FOR SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Barium" as an intervention, any sponsor and status, largest first.
- Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid.Pivotal-lookingCompleted
Fundación Canaria Rafael Clavijo para la Investigación BiomédicaAcademic, hospital or other
NCT02073552 · 472 participants · Start May 2014 · Primary completion Dec 2015
Drug: Polyethylene glycol 4000; Macrogol 3350 plus ascorbic acid · For: Colonoscopy Preparation
Sites: Santa Cruz de Tenerife, Spain
Mayo ClinicAcademic, hospital or other
NCT05541016 · 455 participants (planned) · Start Mar 20, 2023 · Primary completion Sep 6, 2029
Drug: Cisplatin; Docetaxel · For: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 and 4 more
Sites: Scottsdale, Arizona; Jacksonville, Florida; Rochester, Minnesota
- A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00620035 · 301 participants · Start Mar 2007 · Primary completion Oct 2010
Drug: Radiopaque Etonogestrel Implant · For: Contraception
- Cleansing Options in Out-Patient Setting to Improve Tolerance (COOP SIT) TrialPivotal-lookingRecruiting
Morehouse School of MedicineAcademic, hospital or other
NCT07215000 · 300 participants (planned) · Start Oct 1, 2025 · Primary completion Jan 2027
Drug: Golytely; Sulfave and 1 more · For: Colorectal Cancer Screening; Bowel Cleansing for Colonoscopy
Sites: Atlanta, Georgia
- Cough, Expiratory Training, and Chronic Aspiration After Head and Neck RadiotherapyActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT02662907 · 175 participants · Start Feb 1, 2016 · Primary completion Feb 2, 2027
Drug: Barium · For: Head and Neck Cancer
Sites: Houston, Texas
University of FloridaAcademic, hospital or other
NCT02390089 · 158 participants · Start Apr 2015 · Primary completion Feb 10, 2017
Drug: Capsaicin vapor · For: Parkinson's Disease
Sites: Gainesville, Florida
- Optimisation and Performance of Reduced Preparation CT ColographyPivotal-lookingCompleted
London North West Healthcare NHS TrustAcademic, hospital or other
NCT00212433 · 120 participants · Start Jul 2004
Drug: Tagitol V, Lo So, Readi-Cat 2 · For: Patients With Potential Colorectal Neoplasia
Sites: London, United Kingdom; Oxford, United Kingdom · 3 sites in all
- A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00620464 · 108 participants · Start May 2005 · Primary completion Feb 2009
Drug: Radiopaque Implanon; Implanon (etonogestrel implant) · For: Contraception
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- aspiration68
- no adverse event25
- renal failure18
- acute kidney injury17
- urticaria16
- chronic kidney disease15
- diarrhoea15
- dyspnoea15
- rash14
- cough13
- pruritus13
- vomiting13
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 8 |
| 2009 | 4 |
| 2010 | 8 |
| 2011 | 14 |
| 2012 | 12 |
| 2013 | 18 |
| 2014 | 12 |
| 2015 | 9 |
| 2016 | 24 |
| 2017 | 27 |
| 2018 | 18 |
| 2019 | 21 |
| 2020 | 19 |
| 2021 | 75 |
| 2022 | 20 |
| 2023 | 18 |
| 2024 | 10 |
| 2025 | 19 |
| 2026 | 7 |
Recalls
2 FDA enforcement reports for this application.
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Jul 2, 2014 · Class III · Terminated
Subpotent Drug: Low out of specification results for both pH and assay obtained during routine stability testing after 36 months.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Endoscopic findings after CT proven acute diverticulitis: a systematic review and meta-analysis.
Cao AMY, Lam VW, Rickard MJFX · ANZ J Surg 2023 · Meta-Analysis, Systematic Review
- Relationship between maternal heavy metal exposure and congenital heart defects: a systematic review and meta-analysis.
Li S, Wang Q, Luo W, et al. · Environ Sci Pollut Res Int 2022 · Meta-Analysis, Systematic Review
- Quantitative analysis of restricted metals and metalloids in tattoo inks: A systematic review and meta-analysis.
Kiszla BM, Elmets CA, Mayo TT · Chemosphere 2023 · Meta-Analysis, Systematic Review
- Efficacy and safety of Zhishixiaopi decoction in functional dyspepsia: A meta-analysis of randomized controlled trials.
Zhao X, Cheng X, Ye J, et al. · PLoS One 2024 · Meta-Analysis, Systematic Review
- Exposure to potentially toxic elements (PTEs) and the risk of male infertility- A Systematic review and meta-analysis.
Kaur M, Ghosal A, Kaur R, et al. · J Gynecol Obstet Hum Reprod 2024 · Systematic Review, Meta-Analysis
- Cruroplasty with or without mesh? A systematic literature review with a novel time-organized proportion meta-analysis.
Latorre-Rodríguez AR, Rajan A, Mittal SK · Surg Endosc 2024 · Systematic Review, Meta-Analysis
Sponsor: Bracco · Also marketed as E-Z-Hd, Varibar Thin Liquid, E-Z-Paque
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.